サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1654201

創薬アウトソーシング市場規模、シェア、動向分析レポート：医薬品タイプ別、ワークフロー別、治療領域別、サービスタイプ別、最終用途別、地域別、セグメント予測、2025年～2030年

Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Drug Type (Small, Large Molecules), By Workflow, By Therapeutics Area, By Service Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
創薬アウトソーシング市場規模、シェア、動向分析レポート：医薬品タイプ別、ワークフロー別、治療領域別、サービスタイプ別、最終用途別、地域別、セグメント予測、2025年～2030年
出版日: 2025年01月13日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

創薬アウトソーシング市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の創薬アウトソーシング市場規模は2030年までに102億3,000万米ドルに達し、2025～2030年のCAGRは7.58％で拡大する見込みです。

創薬はコストと時間のかかるプロセスです。このため、製薬会社やバイオテクノロジー会社は、研究活動を学術機関や非公開会社（CRO）にアウトソーシングすることを選択しています。公的機関や民間企業間の提携の増加は創薬プロセスを加速させ、その結果、創薬のためのアウトソーシングサービスの世界の需要が増加しています。

このシナリオは、COVID後も継続すると予想されます。慢性疾患患者の増加により、企業は寿命を延ばす医薬品の開発を強く求められています。国連によると、2015～2020年の間に65歳になる人の寿命は17年延びると予想されています。企業がアウトソーシングに積極的に取り組んでいる主要治療領域には、がん、循環器、抗感染症薬などがあります。2020年11月、AstraZenecaは、最も治療が困難とされるがんの研究を促進するため、9つの主要ながん医療センターと提携しました。同社は、このネットワークのメンバーからの臨床と非臨床研究提案に資金を提供する予定です。

COVID-19の大流行は、創薬と開発の価値を実証しました。世界中の人々がワクチンを待ち望んでいる一方で、複数の企業がCOVID-19に対抗する効果的なワクチンの開発に積極的に取り組んでいます。PfizerとBioNTech SEは、このウイルスと闘う可能性のある株の世界の第3相臨床検査後、ワクチンの最初の承認を受けた。臨床検査に関しては、その多くが中止されているが、遠隔モニタリング技術を採用することで機能しているものもあります。このように、パンデミックは、創薬アウトソーシングがウイルスに対する効果的な治療法を開発するための重要な側面となり、製薬産業の中心舞台をもたらしました。このため、今後2年間は短期的なブームとして市場収益を押し上げ、その後は本来の成長曲線を取り戻すと予想されます。

創薬アウトソーシング市場レポートハイライト

  • ワークフローセグメントに基づき、市場は対象同定＆スクリーニング、対象検証＆機能インフォマティクス、リード同定＆候補最適化、前臨床開発、その他関連ワークフローに区分されます。
  • 治療セグメント別では、呼吸器系、疼痛・麻酔、腫瘍、眼科、血液、循環器、内分泌、消化器、免疫調節、抗感染、中枢神経、皮膚、泌尿生殖器に区分されます。
  • 医薬品タイプ別では、市場は低分子と高分子（バイオ医薬品）に区分されます。
  • サービスタイプ別では、市場は化学的サービスと生物学的サービスに区分されます。化学的セグメントは、産業全体で低分子のアウトソーシングプロジェクトが増加していることから、2024年の売上高シェアで最大を占めました。
  • 最終用途別では、市場は製薬・バイオテクノロジー企業、学術機関、その他に区分されます。2024年には、製薬・バイオテクノロジー企業が最大の収益シェアを占め、市場を独占しました。
  • アジア太平洋市場は2024年に45.99%の最大市場シェアを占めました。この成長は、医療支出の増加や医薬品需要の増加など、さまざまな要因によるものと考えられます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 創薬アウトソーシング市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/補助市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 創薬アウトソーシング市場分析ツール
    • 産業分析-ポーターの5つの分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 創薬アウトソーシング市場：ワークフロー別、推定・動向分析

  • 創薬アウトソーシング市場、ワークフロー別：セグメントダッシュボード
  • 創薬アウトソーシング市場、ワークフロー別：変動分析
  • ワークフロー別、2018～2030年
  • 対象同定＆スクリーニング
  • 対象検証＆機能インフォマティクス
  • リード同定＆候補最適化
  • 前臨床開発
  • その他

第5章 創薬アウトソーシング市場：治療領域別、推定・動向分析

  • 創薬アウトソーシング市場、治療領域別：セグメントダッシュボード
  • 創薬アウトソーシング市場、治療領域別：変動分析
  • 治療領域別、2018～2030年
  • 呼吸器系
  • 疼痛・麻酔
  • 腫瘍
  • 眼科
  • 血液
  • 循環器
  • 内分泌
  • 消化器
  • 免疫調節
  • 抗感染
  • 中枢神経
  • 皮膚科
  • 泌尿生殖器

第6章 創薬アウトソーシング市場：医薬品タイプ別、推定・動向分析

  • 創薬アウトソーシング市場、医薬品タイプ別：セグメントダッシュボード
  • 創薬アウトソーシング市場、医薬品タイプ別：変動分析
  • 医薬品タイプ別、2018～2030年
  • 低分子
    • 低分子市場、2018～2030年、
  • 高分子（バイオ医薬品）
    • 高分子（バイオ医薬品）市場、2018～2030年、

第7章 創薬アウトソーシング市場：サービスタイプ別、推定・動向分析

  • 創薬アウトソーシング市場、サービスタイプ別：セグメントダッシュボード
  • 創薬アウトソーシング市場、サービスタイプ別：変動分析
  • サービスタイプ別、2018～2030年
  • 化学的サービス
    • 化学的サービス市場、2018～2030年、
  • 生物学的サービス
    • 生物学的サービス市場、2018～2030年、

第8章 創薬アウトソーシング市場：最終用途別、推定・動向分析

  • 創薬アウトソーシング市場、最終用途別：セグメントダッシュボード
  • 創薬アウトソーシング市場、最終用途別：変動分析
  • 最終用途別、2018～2030年
  • 製薬・バイオテクノロジー企業
    • 製薬・バイオテクノロジー企業市場、2018～2030年、
  • 学術機関
    • 学術機関市場、2018～2030年、

第9章 創薬アウトソーシング市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 世界地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • フランス
    • スペイン
    • オランダ
    • ベルギー
    • スイス
    • ロシア
    • スウェーデン
  • アジア太平洋
    • 中国
    • 日本
    • オーストラリア
    • 韓国
    • インド
    • タイ
    • マレーシア
    • インドネシア
    • シンガポール
    • フィリピン
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
    • コロンビア
    • チリ
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート
    • イスラエル
    • エジプト

第10章 競合情勢

  • 市場参入企業の分類
  • 企業市場シェア分析、2024年
  • 企業プロファイル
    • Albany Molecular Research Inc.
    • EVOTEC
    • Laboratory Corporation of America Holdings
    • GenScript
    • Pharmaceutical Product Development, LLC
    • Charles River Laboratories
    • WuXi AppTec
    • Merck &Co., Inc.
    • Thermo Fisher Scientific Inc
    • Dalton Pharma Services
    • Oncodesign
    • Jubilant Biosys
    • DiscoverX Corp.
    • QIAGEN
    • Eurofins SE
    • Syngene International Limited
    • Dr. Reddy Laboratories Ltd.
    • Pharmaron Beijing Co., Ltd.
    • TCG Lifesciences Pvt Ltd.
    • Domainex Ltd.
図表

List of Tables

  • Table. 1 List of Secondary Sources
  • Table. 2 List of Abbreviations
  • Table. 3 Global Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 4 Global Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 5 Global Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 6 Global Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 7 Global Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 8 North America Discovery Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 9 North America Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 10 North America Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 11 North America Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 12 North America Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 13 North America Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 14 U.S. Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 15 U.S. Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 16 U.S. Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 17 U.S. Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 18 U.S. Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 19 Canada Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 20 Canada Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 21 Canada Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 22 Canada Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 23 Canada Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 24 Mexico Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 25 Mexico Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 26 Mexico Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 27 Mexico Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 28 Mexico Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 29 Europe Discovery Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 30 Europe Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 31 Europe Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 32 Europe Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 33 Europe Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 34 Europe Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 35 Germany Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 36 Germany Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 37 Germany Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 38 Germany Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 39 Germany Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 40 UK Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 41 UK Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 42 UK Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 43 UK Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 44 UK Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 45 France Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 46 France Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 47 France Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 48 France Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 49 France Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 50 Italy Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 51 Italy Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 52 Italy Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 53 Italy Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 54 Italy Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 55 Spain Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 56 Spain Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 57 Spain Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 58 Spain Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 59 Spain Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 60 Netherland Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 61 Netherland Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 62 Netherland Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 63 Netherland Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 64 Netherland Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 65 Belgium Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 66 Belgium Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 67 Belgium Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 68 Belgium Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 69 Belgium Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 70 Switzerland Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 71 Switzerland Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 72 Switzerland Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 73 Switzerland Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 74 Switzerland Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 75 Russia Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 76 Russia Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 77 Russia Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 78 Russia Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 79 Russia Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 80 Sweden Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 81 Sweden Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 82 Sweden Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 83 Sweden Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 84 Sweden Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 85 Asia Pacific Discovery Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 86 Asia Pacific Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 87 Asia Pacific Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 88 Asia Pacific Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 89 Asia Pacific Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 90 Asia Pacific Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 91 Japan Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 92 Japan Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 93 Japan Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 94 Japan Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 95 Japan Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 96 China Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 97 China Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 98 China Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 99 China Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 100 China Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 101 India Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 102 India Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 103 India Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 104 India Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 105 India Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 106 Thailand Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 107 Thailand Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 108 Thailand Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 109 Thailand Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 110 Thailand Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 111 South Korea Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 112 South Korea Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 113 South Korea Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 114 South Korea Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 115 South Korea Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 116 Australia Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 117 Australia Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 118 Australia Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 119 Australia Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 120 Australia Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 121 Malaysia Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 122 Malaysia Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 123 Malaysia Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 124 Malaysia Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 125 Malaysia Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 126 Indonesia Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 127 Indonesia Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 128 Indonesia Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 129 Indonesia Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 130 Indonesia Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 131 Singapore Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 132 Singapore Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 133 Singapore Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 134 Singapore Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 135 Singapore Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 136 Philippines Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 137 Philippines Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 138 Philippines Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 139 Philippines Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 140 Philippines Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 141 Latin America Discovery Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 142 Latin America Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 143 Latin America Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 144 Latin America Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 145 Latin America Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 146 Latin America Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 147 Brazil Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 148 Brazil Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 149 Brazil Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 150 Brazil Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 151 Brazil Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 152 Argentina Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 153 Argentina Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 154 Argentina Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 155 Argentina Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 156 Argentina Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 157 Colombia Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 158 Colombia Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 159 Colombia Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 160 Colombia Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 161 Colombia Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 162 Chile Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 163 Chile Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 164 Chile Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 165 Chile Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 166 Chile Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 167 Middle East & Africa Discovery Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 168 Middle East & Africa Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 169 Middle East & Africa Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 170 Middle East & Africa Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 171 Middle East & Africa Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 172 Middle East & Africa Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 173 South Africa Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 174 South Africa Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 175 South Africa Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 176 South Africa Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 177 South Africa Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 178 Saudi Arabia Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 179 Saudi Arabia Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 180 Saudi Arabia Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 181 Saudi Arabia Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 182 Saudi Arabia Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 183 UAE Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 184 UAE Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 185 UAE Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 186 UAE Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 187 UAE Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 188 Israel Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 189 Israel Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 190 Israel Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 191 Israel Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 192 Israel Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 193 Egypt Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 194 Egypt Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 195 Egypt Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 196 Egypt Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 197 Egypt Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 198 Regulations for pharmaceutical Workflows and Drug Types in the U.S.
  • Table. 199 Financial performance

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 Drug discovery outsourcing market dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Drug Discovery Outsourcing market: Workflow outlook and key takeaways
  • Fig. 20 Clinical Trial Biorepository & Archiving Solutions market: Workflow movement analysis
  • Fig. 21 Target Identification & Screening market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Target Validation & Functional Informatics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Lead Identification & Candidate Optimization market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Preclinical Development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Other Associated Workflow market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Drug Discovery Outsourcing market: Therapeutics Area outlook and key takeaways
  • Fig. 27 Clinical Trial Biorepository & Archiving Solutions market: Therapeutics Area movement analysis
  • Fig. 28 Respiratory system market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Pain and Anesthesia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Ophthalmology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Hematology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Endocrine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Gastrointestinal market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Immunomodulation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Anti-infective market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Central Nervous System market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Dermatology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Genitourinary System market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Drug Discovery Outsourcing market: Drug Type outlook and key takeaways
  • Fig. 42 Clinical Trial Biorepository & Archiving Solutions market: Drug Type movement analysis
  • Fig. 43 Small Molecules market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Large Molecules (Biopharmaceuticals) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Drug Discovery Outsourcing market: Service Type outlook and key takeaways
  • Fig. 46 Clinical Trial Biorepository & Archiving Solutions market: Service Type movement analysis
  • Fig. 47 Chemistry Services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Biology Services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Drug Discovery Outsourcing market: End Use outlook and key takeaways
  • Fig. 50 Clinical Trial Biorepository & Archiving Solutions market: End Use movement analysis
  • Fig. 51 Academic Institutes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Regional Marketplace: Key Takeaways
  • Fig. 53 North America drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 U.S. drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Canada drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Mexico drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Europe drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 UK drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Germany drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 France drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Italy drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Spain drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Netherland outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Belgium outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Switzerland outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Russia outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Sweden outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Denmark drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Asia Pacific drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Japan drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 China drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 India drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Thailand drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 South Korea drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Australia drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Malaysia drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Indonesia drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 Singapore drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Philippines drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Latin America drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Brazil drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Key country dynamics
  • Fig. 109 Argentina drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key country dynamics
  • Fig. 111 Colombia drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Key country dynamics
  • Fig. 113 Chile drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 MEA drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Key country dynamics
  • Fig. 116 South Africa drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Fig. Key country dynamics
  • Fig. 118 Saudi Arabia drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Key country dynamics
  • Fig. 120 UAE drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 121 Key country dynamics
  • Fig. 122 Israel drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 123 Key country dynamics
  • Fig. 124 Egypt drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 125 Key country dynamics
  • Fig. 126 Kuwait drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 127 Key company categorization
  • Fig. 128 Service heat map analysis
  • Fig. 129 Strategic framework
目次
Product Code: GVR-2-68038-392-8

Drug Discovery Outsourcing Market Growth & Trends:

The global drug discovery outsourcing market size is expected to reach USD 10.23 billion by 2030 and is expected to expand at a CAGR of 7.58% from 2025 to 2030, according to a new report by Grand View Research, Inc., The COVID-19 pandemic has brought pharmaceutical companies in limelight. Drug discovery is a costly and lengthy process. This has urged pharmaceutical and biotech companies to opt for outsourcing their research activities to academic and private Contract Research Organizations (CROs). Rising partnerships between public or private entities accelerate drug discovery processes, which, in turn, increase the global demand for outsourcing services for drug discovery.

This scenario is expected to sustain post-Covid implications as well. A rise in cases of chronic diseases has urged companies to develop medicines that extend life expectancy. According to the United Nations, people aged 65 years between 2015 and 2020 are expected to live an additional 17 years. Some of the key therapeutic areas where companies are actively involved in outsourcing include oncology, cardiovascular, and anti-infectives. In November 2020, AstraZeneca collaborated with 9 of the foremost oncology medical centers to expedite research in some of the hardest-to-treat cancers. The company will be funding clinical and non-clinical research proposals from members of this network.

The COVID-19 pandemic has demonstrated the value of drug discovery and development. People across the world are waiting for a vaccine while several companies are proactively involved in developing an effective vaccine to combat COVID-19. Pfizer Inc. and BioNTech SE received first approval for the vaccine following a worldwide Phase 3 trial of a potential strain to combat the virus. As for clinical trials, many of them are halted, while some are functional by adopting remote monitoring technologies. Thus, the pandemic has brought the pharmaceutical industry to center stage with drug discovery outsourcing becoming a key aspect to develop effective treatments against the virus. This is expected to boost the market revenue for the next 2 years i.e. a short-term boom, after which it shall regain its original growth curve.

Drug Discovery Outsourcing Market Report Highlights:

  • On the basis of workflow segment, the market is segmented into target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and other associated workflow.
  • On the basis of therapeutics area segment, the market is segmented into Respiratory System, Pain and Anesthesia, Oncology, Ophthalmology, Hematology, Cardiovascular, Endocrine, Gastrointestinal, Immunomodulation, Anti-Infective, Central Nervous System, Dermatology, and Genitourinary System.
  • On the basis of drug type segment, the market is segmented into Small Molecules, and Large Molecules (Biopharmaceuticals).
  • On the basis of service type segment, the market is segmented into Chemistry Services, and Biology Services. The chemistry segment dominated the market with the largest revenue share in 2024, owing to increasing number of outsourcing projects for small molecules across the industry.
  • On the basis of end use segment, the market is segmented into Pharmaceutical & Biotechnology companies, Academic Institutes, and Others. The pharmaceutical & biotechnology companies segment dominated the market with the largest revenue share in 2024.
  • Asia Pacific market held the largest market share of 45.99% in 2024. This growth can be attributed to various factors, such as rising healthcare expenditure and growing demand for pharmaceutical products.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Workflow
    • 1.2.2. Therapeutics Area
    • 1.2.3. Drug type
    • 1.2.4. Service Type
    • 1.2.5. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Drug Discovery Outsourcing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing R&D In Biopharmaceutical Industry
      • 3.2.1.2. Increasing demand for outsourcing Services in Drug Development
      • 3.2.1.3. Increasing number of partnerships in drug discovery research
      • 3.2.1.4. Technological advancements in drug discovery
      • 3.2.1.5. Rising incidence rate of metabolic, genetic, and other chronic diseases
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of open-source software packages for drug discovery
      • 3.2.2.2. High manufacturing costs coupled with high risk of drug failure
  • 3.3. Drug Discovery Outsourcing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

  • 4.1. Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
  • 4.2. Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
  • 4.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2018 - 2030
  • 4.4. Target Identification & Screening
    • 4.4.1. Target Identification & Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Target Validation & Functional Informatics
    • 4.5.1. Target Validation & Functional Informatics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Lead Identification & Candidate Optimization
    • 4.6.1. Lead Identification & Candidate Optimization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Preclinical Development
    • 4.7.1. Preclinical Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Other Associate Workflow
    • 4.8.1. Other Associate Workflow Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

  • 5.1. Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
  • 5.2. Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
  • 5.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics, 2018 - 2030
  • 5.4. Respiratory System
    • 5.4.1. Respiratory System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Pain and Anesthesia
    • 5.5.1. Pain and Anesthesia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Oncology
    • 5.6.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Ophthalmology
    • 5.7.1. Ophthalmology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Hematology
    • 5.8.1. Hematology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Cardiovascular
    • 5.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.10. Endocrine
    • 5.10.1. Endocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.11. Gastrointestinal
    • 5.11.1. Gastrointestinal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.12. Immunomodulation
    • 5.12.1. Immunomodulation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.13. Anti-Infective
    • 5.13.1. Anti-Infective Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.14. Central Nervous System
    • 5.14.1. Central Nervous System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.15. Dermatology
    • 5.15.1. Dermatology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.16. Genitourinary System
    • 5.16.1. Genitourinary System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Drug Discovery Outsourcing Market: Drug Type Estimates & Trend Analysis

  • 6.1. Drug Discovery Outsourcing Market, By Drug Type: Segment Dashboard
  • 6.2. Drug Discovery Outsourcing Market, By Drug Type: Movement Analysis
  • 6.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Drug Type, 2018 - 2030
  • 6.4. Small Molecules
    • 6.4.1. Small Molecules Market, 2018 to 2030, (USD Million)
  • 6.5. Large Molecules (Biopharmaceuticals)
    • 6.5.1. Large Molecules (Biopharmaceuticals) Market, 2018 to 2030, (USD Million)

Chapter 7. Drug Discovery Outsourcing Market: Service Type Estimates & Trend Analysis

  • 7.1. Drug Discovery Outsourcing Market, By Service Type: Segment Dashboard
  • 7.2. Drug Discovery Outsourcing Market, By Service Type: Movement Analysis
  • 7.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Service Type, 2018 - 2030
  • 7.4. Chemistry Services
    • 7.4.1. Chemistry Services Market, 2018 to 2030, (USD Million)
  • 7.5. Biology Services
    • 7.5.1. Biology Services Market, 2018 to 2030, (USD Million)

Chapter 8. Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

  • 8.1. Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
  • 8.2. Drug Discovery Outsourcing Market, By End Use: Movement Analysis
  • 8.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2018 - 2030
  • 8.4. Pharmaceutical & Biotechnology companies
    • 8.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 to 2030, (USD Million)
  • 8.5. Academic Institutes
    • 8.5.1. Academic Institutes Market, 2018 to 2030, (USD Million)

Chapter 9. Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2024 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Global Regional Market Snapshot
  • 9.4. North America
    • 9.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. U.S
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Competitive Scenario
      • 9.4.2.3. Regulatory Framework
      • 9.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. Canada
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Competitive Scenario
      • 9.4.3.3. Regulatory Framework
      • 9.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. Mexico
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Competitive Scenario
      • 9.4.4.3. Regulatory Framework
      • 9.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Europe
    • 9.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. UK
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Competitive Scenario
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. Germany
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Competitive Scenario
      • 9.5.3.3. Regulatory Framework
      • 9.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.4. Italy
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Competitive Scenario
      • 9.5.4.3. Regulatory Framework
      • 9.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.5. France
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Competitive Scenario
      • 9.5.5.3. Regulatory Framework
      • 9.5.5.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.6. Spain
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Competitive Scenario
      • 9.5.6.3. Regulatory Framework
      • 9.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.7. Netherland
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Competitive Scenario
      • 9.5.7.3. Regulatory Framework
      • 9.5.7.4. Netherland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.8. Belgium
      • 9.5.8.1. Key Country Dynamics
      • 9.5.8.2. Competitive Scenario
      • 9.5.8.3. Regulatory Framework
      • 9.5.8.4. Belgium Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.9. Switzerland
      • 9.5.9.1. Key Country Dynamics
      • 9.5.9.2. Competitive Scenario
      • 9.5.9.3. Regulatory Framework
      • 9.5.9.4. Switzerland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.10. Russia
      • 9.5.10.1. Key Country Dynamics
      • 9.5.10.2. Competitive Scenario
      • 9.5.10.3. Regulatory Framework
      • 9.5.10.4. Russia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.11. Sweden
      • 9.5.11.1. Key Country Dynamics
      • 9.5.11.2. Competitive Scenario
      • 9.5.11.3. Regulatory Framework
      • 9.5.11.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. China
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Competitive Scenario
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. Japan
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Competitive Scenario
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4. Australia
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Competitive Scenario
      • 9.6.4.3. Regulatory Framework
      • 9.6.4.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5. South Korea
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Competitive Scenario
      • 9.6.5.3. Regulatory Framework
      • 9.6.5.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.6. India
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Competitive Scenario
      • 9.6.6.3. Regulatory Framework
      • 9.6.6.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.7. Thailand
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Competitive Scenario
      • 9.6.7.3. Regulatory Framework
      • 9.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.8. Malaysia
      • 9.6.8.1. Key Country Dynamics
      • 9.6.8.2. Competitive Scenario
      • 9.6.8.3. Regulatory Framework
      • 9.6.8.4. Malaysia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.9. Indonesia
      • 9.6.9.1. Key Country Dynamics
      • 9.6.9.2. Competitive Scenario
      • 9.6.9.3. Regulatory Framework
      • 9.6.9.4. Indonesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.10. Singapore
      • 9.6.10.1. Key Country Dynamics
      • 9.6.10.2. Competitive Scenario
      • 9.6.10.3. Regulatory Framework
      • 9.6.10.4. Singapore Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.11. Philippines
      • 9.6.11.1. Key Country Dynamics
      • 9.6.11.2. Competitive Scenario
      • 9.6.11.3. Regulatory Framework
      • 9.6.11.4. Philippines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7. Latin America
    • 9.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.7.2. Brazil
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Competitive Scenario
      • 9.7.2.3. Regulatory Framework
      • 9.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.7.3. Argentina
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Competitive Scenario
      • 9.7.3.3. Regulatory Framework
      • 9.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.7.4. Colombia
      • 9.7.4.1. Key Country Dynamics
      • 9.7.4.2. Competitive Scenario
      • 9.7.4.3. Regulatory Framework
      • 9.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.7.5. Chile
      • 9.7.5.1. Key Country Dynamics
      • 9.7.5.2. Competitive Scenario
      • 9.7.5.3. Regulatory Framework
      • 9.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8. MEA
    • 9.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.8.2. South Africa
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. Competitive Scenario
      • 9.8.2.3. Regulatory Framework
      • 9.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Competitive Scenario
      • 9.8.3.3. Regulatory Framework
      • 9.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.8.4. UAE
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. Competitive Scenario
      • 9.8.4.3. Regulatory Framework
      • 9.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Competitive Scenario
      • 9.8.5.3. Regulatory Framework
      • 9.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.8.6. Israel
      • 9.8.6.1. Key Country Dynamics
      • 9.8.6.2. Competitive Scenario
      • 9.8.6.3. Regulatory Framework
      • 9.8.6.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.8.7. Egypt
      • 9.8.7.1. Key Country Dynamics
      • 9.8.7.2. Competitive Scenario
      • 9.8.7.3. Regulatory Framework
      • 9.8.7.4. Egypt Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Market Participant Categorization
  • 10.2. Company Market Share Analysis, 2024
  • 10.3. Company Profiles
    • 10.3.1. Albany Molecular Research Inc.
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. EVOTEC
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Laboratory Corporation of America Holdings
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. GenScript
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Pharmaceutical Product Development, LLC
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Charles River Laboratories
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. WuXi AppTec
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Merck & Co., Inc.
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Thermo Fisher Scientific Inc
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Dalton Pharma Services
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Oncodesign
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Service Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Jubilant Biosys
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Service Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. DiscoverX Corp.
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Financial Performance
      • 10.3.13.3. Service Benchmarking
      • 10.3.13.4. Strategic Initiatives
    • 10.3.14. QIAGEN
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Financial Performance
      • 10.3.14.3. Service Benchmarking
      • 10.3.14.4. Strategic Initiatives
    • 10.3.15. Eurofins SE
      • 10.3.15.1. Company Overview
      • 10.3.15.2. Financial Performance
      • 10.3.15.3. Service Benchmarking
      • 10.3.15.4. Strategic Initiatives
    • 10.3.16. Syngene International Limited
      • 10.3.16.1. Company Overview
      • 10.3.16.2. Financial Performance
      • 10.3.16.3. Service Benchmarking
      • 10.3.16.4. Strategic Initiatives
    • 10.3.17. Dr. Reddy Laboratories Ltd.
      • 10.3.17.1. Company Overview
      • 10.3.17.2. Financial Performance
      • 10.3.17.3. Service Benchmarking
      • 10.3.17.4. Strategic Initiatives
    • 10.3.18. Pharmaron Beijing Co., Ltd.
      • 10.3.18.1. Company Overview
      • 10.3.18.2. Financial Performance
      • 10.3.18.3. Service Benchmarking
      • 10.3.18.4. Strategic Initiatives
    • 10.3.19. TCG Lifesciences Pvt Ltd.
      • 10.3.19.1. Company Overview
      • 10.3.19.2. Financial Performance
      • 10.3.19.3. Service Benchmarking
      • 10.3.19.4. Strategic Initiatives
    • 10.3.20. Domainex Ltd.
      • 10.3.20.1. Company Overview
      • 10.3.20.2. Financial Performance
      • 10.3.20.3. Service Benchmarking
      • 10.3.20.4. Strategic Initiatives